not tagged
not tagged
['lymsm', 'car-t', 'lymphoma']
#eha2022 | won seog kim, samsung medical center presented a phase i/ii study investigating anbal-cel, an anti-cd19 car-t therapy in r/r lbcl. cr rate, 82%. of 11 pts, 5 had crs; 4 were grade 1/2 and one grade 3. one pt dosed at dl3 experienced a grade 2 ne #lymphoma #lymsm 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm